帯状疱疹後神経痛治療市場レポート：2031年までの動向、予測、競合分析

帯状疱疹後神経痛治療薬の世界市場の将来性は、病院薬局、オンライン薬局、小売薬局市場での機会により有望視されています。世界の帯状疱疹後神経痛治療市場は、2025年から2031年にかけてCAGR 4.0％で成長すると予測されます。この市場の主な促進要因は、帯状疱疹の罹患率の上昇、帯状疱疹後神経痛の認知度の向上、高度な治療オプションの増加です。

• Lucintelの予測では、タイプ別では抗けいれん薬が予測期間中に高い成長を遂げる見込みです。
• 用途別では、小売薬局が最も高い成長が見込まれます。
• 地域別では、北米が予測期間中に最も高い成長が見込まれます。

帯状疱疹後神経痛治療市場の新たな動向

帯状疱疹後神経痛治療市場は、患者のケアと治療に革命をもたらすいくつかの新たな動向を目の当たりにしています。これらの動向は、技術の進歩から患者の行動や治療パラダイムの変化まで様々です。世界中でPHNの罹患率が増加する中、これらの動向は市場の進路に影響を与え、拡大と成長のための新たな道を提示しています。

• 遠隔医療の統合：遠隔医療もまた、PHN管理、特に遠隔モニタリングと疼痛管理のために急成長している動向です。オンライン・ヘルス・プラットフォームが普及するにつれて、患者は対面での診察を必要とせず、自宅にいながら遠隔で専門医と面談できるようになりました。遠隔医療は、地方や十分なサービスを受けていない地域の患者にとって、手頃で便利なソリューションです。
• 個別化医療：個別化医療は、PHNの管理においてますます重要な役割を果たすようになってきており、ヘルスケア専門家が患者個人の遺伝子プロファイル、既往歴、正確なニーズに従って治療法をカスタマイズすることを可能にしています。ゲノム検査を実施し、プレシジョンメディシン（精密医療）療法を開発する動向の高まりは、PHN管理に革命をもたらしています。パーソナライズされた戦略は、臨床医が最適な治療法を選択する手助けをし、それによって患者の転帰を向上させ、副作用を最小限に抑えます。
• 再生医療：幹細胞治療や組織再生を含む再生医療治療は、PHN治療の可能性として検討されています。これらの治療法は、神経の傷害を治し、正常な機能を回復させようとするもので、PHN患者に長期的な緩和をもたらす可能性があります。この方向での研究はまだ始まったばかりであるが、近い将来、再生治療がPHNの治療に革命をもたらすことが期待されています。
• 併用療法：薬理学的療法と非薬理学的療法を組み合わせた併用療法は、PHN治療の効果的なアプローチとして脚光を浴びています。経口薬と局所療法、神経刺激装置、理学療法を併用することで、患者は痛みの軽減と生活の質の向上を示しています。PHN患者により総合的な治療を提供しようとする医療提供者により、複数の治療法が注目されるようになり、市場の成長に拍車をかけています。
• 一般用医薬品：患者が医師の診察を受けずに軽度の症状を治療できるよう、市販のPHN治療薬を開発する機運が高まっています。OTCクリーム、パッチ、内服薬は、利便性と手ごろな価格から人気を集めています。このセルフメディケーションの動向は、医療へのアクセスが制限されている市場では特に重要です。

このような新しい動向により、帯状疱疹後神経痛治療市場は、アクセシビリティの向上、治療選択肢の拡大、患者への個別化治療の提供によって変貌を遂げつつあります。デジタルツールの使用、再生医療の拡大、併用療法の導入は、より効率的で効果的な治療につながっています。このような動向が進化を続けるにつれ、PHNの治療環境は大きな変化を遂げ、患者により良い結果をもたらし、市場に新たな成長機会を生み出すことになると思われます。

帯状疱疹後神経痛治療市場の最近の動向

帯状疱疹後神経痛治療市場は、ここ数年で大きな成長を遂げています。帯状疱疹後神経痛は依然として世界的に数百万人の患者に影響を及ぼしており、新たな治療法や開発が視野に入りつつあります。製薬会社や研究者は、新しい治療手法、有効性の向上、患者の転帰に注力しています。新薬の上市、最先端技術、PHNを特徴づける障害をもたらす痛みを和らげる治療アプローチの改善により、市場は変貌を遂げつつあります。

• 医薬品開発の進展：ここ数年、帯状疱疹後神経痛の新薬開発が大幅に進展しています。カプサイシンパッチや長時間作用型オピオイドなどの新薬の導入は、PHNの治療を大きく変えました。これらの薬剤は、より少ない副作用で持続的に痛みを緩和し、患者の生活の質を高めることを目標としています。また、新しいドラッグデリバリーシステムに関する研究の増加も、治療効果を高める可能性を秘めています。
• 非オピオイド鎮痛療法の出現：非オピオイド療法は、PHNに対するオピオイドベースの治療法よりも安全な選択肢として勢いを増しています。リドカイン、ガバペンチン、プレガバリンなどの薬剤は、オピオイドの危険性を伴わずに神経痛の緩和に有効であることが証明されました。市場では、オピオイド依存や副作用への懸念から、これらの治療法の受容が拡大しており、非オピオイド療法への需要が高まっています。
• 治療計画における遠隔医療の統合：遠隔医療は、PHNの治療を劇的に変化させました。遠隔医療プラットフォームは現在、遠隔診療を提供するために広く利用されており、患者は自分の状態をよりよく管理できるようになりました。これにより、特に地方の患者や十分な治療を受けていない患者のヘルスケアへのアクセスが拡大し、患者の経過観察や治療のリアルタイム調整が容易になりました。
• 神経調節技術の進歩：経頭蓋磁気刺激（TMS）や脊髄刺激などの神経調節療法は、PHNの治療に有望な結果を示しています。これらの治療法は、神経活動を変化させることで、痛みの知覚を減少させる。これらの技術がより洗練され、侵襲性が低くなるにつれて、治療レジメンに組み込まれるようになり、従来の薬物療法がうまくいかなかった場合に、患者に代替手段を提供できるようになってきています。
• 個別化医療戦略：個別化医療がますます重視されるようになり、PHN治療法を個人に合わせたものにするのに役立っています。遺伝子研究の進歩により、臨床医が患者の遺伝的体質に応じて最適な治療法を選択できるようになってきています。これにより、より正確で効率的な治療レジメンが可能となり、痛みの軽減と副作用の軽減が実現します。

このような進歩は、患者により効率的で、より安全で、カスタマイズされた選択肢を提供することで、帯状疱疹後神経痛の治療シナリオに革命をもたらしています。新しい治療法や技術革新は、PHNの管理全般を強化し、かつては選択肢がほとんどなかった患者の苦痛を軽減しています。これらの動向はまた、非オピオイド、オーダーメイド、テクノロジー主導のソリューションという、有効性と患者の福祉の両方をバランスよく実現するヘルスケア分野の大きな流れを表しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の帯状疱疹後神経痛治療市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019～2024年）と予測（2025～2031年）
• 帯状疱疹後神経痛治療の世界市場動向（2019～2024年）と予測（2025～2031年）
• タイプ別
  • 抗けいれん薬
  • 皮膚パッチ
  • その他
• 用途別
  • 病院薬局
  • オンライン薬局
  • 小売薬局

第4章 2019年から2031年までの地域別市場動向と予測分析

• 地域別の帯状疱疹後神経痛治療市場
• 北米の帯状疱疹後神経痛治療市場
• 欧州帯状疱疹後神経痛治療市場
• アジア太平洋地域の帯状疱疹後神経痛治療市場
• その他地域帯状疱疹後神経痛治療市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • タイプ別
  • 用途別
  • 地域別
• 世界の帯状疱疹後神経痛治療市場における新たな動向
• 戦略分析
  • 新製品開発
  • 世界の帯状疱疹後神経痛治療市場の能力拡大
  • 世界の帯状疱疹後神経痛治療市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Pfizer
• Arbor Pharma
• Assertio Therapeutics
• Endo Pharma
• Teikoku Pharma
• Teva
• Mylan

The future of the global post herpetic neuralgia treatment market looks promising with opportunities in the hospital pharmacy, online pharmacy, and retail pharmacy markets. The global post herpetic neuralgia treatment market is expected to grow with a CAGR of 4.0% from 2025 to 2031. The major drivers for this market are the rising incidence of shingles, the growing awareness of post-herpetic neuralgia, and the increasing availability of advanced treatment options.

• Lucintel forecasts that, within the type category, anticonvulsant is expected to witness higher growth over the forecast period.
• Within the application category, retail pharmacy is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market is witnessing some emerging trends that are revolutionizing patient care and treatment. These trends vary from technological advancements to changes in patient behavior and treatment paradigms. With an increasing incidence of PHN across the globe, these trends are influencing the path of the market and presenting new avenues for expansion and growth.

• Telemedicine Integration: Telemedicine is also a fast-growing trend for PHN management, particularly for remote monitoring and pain management. As online health platforms proliferate, patients can now remotely meet with specialists in the comfort of their own homes without requiring in-person consultations. Telemedicine is an affordable and convenient solution for patients in rural or underserved locations.
• Personalized Medicine: Personalized medicine is increasingly playing a vital role in the management of PHN, enabling healthcare professionals to customize therapies in accordance with the patient's individual genetic profiles, history, and precise needs. The increasing trend of implementing genomic testing and creating precision medicine therapies is revolutionizing PHN management. Personalized strategies are assisting clinicians in the selection of the best treatments, thereby enhancing patient outcomes and minimizing side effects.
• Regenerative Medicine: Regenerative medicine treatments, including stem cell therapy and tissue regeneration, are being explored as possible PHN therapies. These treatments seek to heal nerve injury and restore normal function, which might provide long-term relief for PHN sufferers. Studies in this direction are in nascent stages, but there is hope that regenerative therapies will revolutionize the treatment of PHN in the near future.
• Combination Therapies: Combination therapies, involving a combination of pharmacological and non-pharmacological therapies, are picking up steam as effective approaches to treating PHN. With the combination of oral drugs and topical therapies, nerve stimulation devices, or physical therapy, patients show improved pain relief and enhanced quality of life. The growing focus on multi-modal treatments is fueling market growth as providers seek to provide more holistic care to PHN patients.
• Over-the-Counter (OTC) Products: There is increasing momentum in the creation of over-the-counter PHN drugs so that patients can treat minor symptoms without seeing a doctor. OTC creams, patches, and oral medications are becoming popular due to convenience and affordability. This trend toward self-medication is particularly critical in markets where access to health care is restricted.

These new trends are transforming the post herpetic neuralgia treatment market by enhancing accessibility, expanding treatment options, and offering more individualized care to patients. The use of digital tools, the expansion of regenerative medicine, and the implementation of combination therapies are leading to more efficient and effective treatments. As these trends continue to evolve, the treatment landscape for PHN will likely undergo significant changes, offering better outcomes for patients and creating new opportunities for growth in the market.

Recent Developments in the Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market has witnessed massive growth in the recent past years. With the condition still impacting millions of patients globally, new treatments and developments are coming into view, resulting in better care and management. Drug firms as well as researchers are concentrating on new treatment methodologies, enhancing efficacy, and patient outcomes. The market is experiencing transformation fueled by novel drug launches, cutting-edge technologies, and improved therapeutic approaches to alleviate the disabling pain that characterizes PHN.

• Progress in Drug Development: In the last few years, there has been substantial advancement in the new drug development for Post-Herpetic Neuralgia. The introduction of new drugs such as capsaicin patches and long-acting opioids has significantly changed the treatment of PHN. These drugs target sustained relief from pain with less side effect, enhancing the quality of life in patients. Increased research into new drug delivery systems also holds the potential for enhancing treatment effectiveness.
• Emergence of Non-Opioid Pain Therapies: Non-opioid therapies are gaining momentum as a more secure option than opioid-based treatments for PHN. Drugs such as lidocaine, gabapentin, and pregabalin proved effective in alleviating nerve pain without the hazards of opioids. The market is experiencing growth in the acceptance of these therapies due to fears of opioid dependency and side effects fueling demand for non-opioid therapies.
• Telemedicine Integration in Treatment Plans: Telemedicine has transformed the treatment of PHN dramatically. Telemedicine platforms are now widely utilized to offer remote consultations, enabling patients to better manage their condition. This has opened up access to healthcare, particularly for rural or underserved patients, and has facilitated easier monitoring of patient progress and real-time adjustment of treatments.
• Advances in Neuromodulation Techniques: Neuromodulation therapies, including transcranial magnetic stimulation (TMS) and spinal cord stimulation, have shown promising results in treating PHN. These therapies work by altering nerve activity to reduce pain perception. As these techniques become more refined and less invasive, they are being integrated into treatment regimens, offering patients alternatives when traditional medications fail.
• Personalized Medicine Strategy: The growing emphasis on personalized medicine is assisting in tailoring PHN therapies to the individual. Breakthroughs in genetic research are making it possible for clinicians to select the most optimal therapies according to a patient's genetic makeup. This enables more precise and efficient treatment regimens, resulting in enhanced pain relief and reduced side effects.

These advancements are revolutionizing the post herpetic neuralgia treatment scenario by providing patients with more efficient, safer, and customized options. New treatments and innovations are enhancing the overall management of PHN, alleviating suffering for those who once had few alternatives. These advancements also represent a larger trend within the healthcare sector towards non-opioid, customized, and technology-driven solutions that balance both efficacy and patient welfare.

Strategic Growth Opportunities in the Post Herpetic Neuralgia Treatment Market

Post herpetic neuralgia treatment market is witnessing a number of growth prospects fueled by innovations, technological breakthroughs, and growing demand for improved solutions. The market is growing as increasing targeted therapies, developments in the mode of delivery of treatments, and growing emphasis on patient-centric care are providing opportunities to grow. Pharmaceutical organizations, healthcare providers, and investors are looking into major applications that will improve treatment and patient outcomes.

• Innovations in Topical Therapies: Topical therapies, including lidocaine and capsaicin patches, are emerging as a major growth opportunity in the PHN market. These treatments deliver localized pain relief with few systemic side effects and are thus a desirable choice for patients who want alternatives to oral drugs. Ongoing innovations in formulation and delivery systems will increase the efficacy and market penetration of topical therapies.
• Growth of Non-Opioid Therapeutics: With increasing need for non-opioid treatment of pain, there is evidently a chance of developing drugs which address the basic mechanisms of PHN without opioid dependency. Emerging molecules like newer anticonvulsants and antidepressants are being researched for better control of nerve pain and provide a new growth opportunity for pharmaceutical companies.
• Telemedicine and Remote Monitoring Solutions: Expansion of telemedicine and digital health technologies is providing opportunities to enhance patient care and treatment outcomes for PHN. Remote monitoring devices, wearable sensors, and mobile health apps can monitor symptoms and modify treatments in real time. This enhances the convenience and accessibility of PHN care, particularly for patients who live in remote locations or have mobility problems.
• Enhanced Neuromodulation Devices: The neuromodulation device market, including spinal cord stimulators and peripheral nerve stimulators, is likely to grow substantially. These devices provide a non-pharmacologic treatment option for PHN and are becoming increasingly popular due to their efficacy and decreased side-effect profile. Increased research and development will further enhance these devices, making them more precise and patient beneficial.
• Personalized Medicine in Pain Relief: Personalized medicine offers a sizeable growth opportunity through the targeting of treatments with genetic and molecular patient profiling. This strategy should maximize pain relief for PHN patients, so that the correct treatments are used for each. The incorporation of genomic information into treatment plans will enhance efficacy and reduce side effects, making personalized therapies a central market driver.

These growth opportunities reflect the trend towards more personalized, non-opioid, and technology-based solutions in the management of post herpetic neuralgia. As these applications mature, they not only enhance patient outcomes but also increase the scope of available treatment options. This makes the market more competitive and diverse, with increased emphasis on patient-centric care, which will fuel market growth in the next few years.

Post Herpetic Neuralgia Treatment Market Driver and Challenges

The post herpetic neuralgia treatment market is driven by a wide range of factors involving technology advancements, economic factors, and regulatory forces. Although many drivers are dominating the growth of the market, some obstacles such as regulatory barriers and treatment constraints are also affecting the rate of growth. Knowledge of these drivers and challenges is essential for stakeholders to steer the changing landscape of PHN treatment successfully.

The factors responsible for driving the post herpetic neuralgia treatment market include:

1. Growing Incidence of Herpes Zoster: One of the key drivers of demand for PHN treatments is the growing incidence of Herpes Zoster (shingles). With the aging of the global population, the number of cases of shingles and its complications, such as PHN, is on the rise. This is fueling the demand for effective treatments and therapies, leading to the expansion of the PHN treatment market.

2. Technological Advances in Treatment Modalities: The quick developments in neuromodulation technologies, customized medicine, and drug delivery devices are having a positive impact on the PHN treatment market. The new developments are making treatments more precise and effective, enhancing patient outcomes, and driving market growth. R&D is being heavily invested in by companies to introduce advanced technologies to the market.

3. Increased Awareness and Rising Diagnosis Rates: Public awareness regarding PHN and its effect on the quality of life of patients has increased over time. Increasing awareness is resulting in early diagnosis and treatment, which is fueling the demand for therapeutic solutions. Physicians are also learning to identify PHN at an early stage, further contributing to market growth.

4. Demand for Non-Opioid Pain Management: Owing to increasing fears over opioid addiction and dependence, demand for non-opioid pain management practices has picked up quite well. Increasing need for substitute treatment methods providing potent pain relief with minimal potential for addiction is pushing the usage of non-opioid treatment in PHN, stimulating the market growth.

5. Government Programs and Funding: Governments globally are realizing the cost of chronic pain conditions such as PHN, and many are providing incentives and funding to stimulate research on new treatments. This funding is stimulating innovation and speeding up the creation of better therapies.

Challenges in the post herpetic neuralgia treatment market are:

1. Regulatory and Approval Delays: One of the biggest challenges in the PHN treatment market is the long and complex approval process for emerging therapies. Delays in regulation can hinder the timely release of new and innovative therapies, limiting market growth and patient access to leading-edge therapies.

2. Limited Efficacy of Current Therapies: Although a variety of PHN treatments are currently available, patients still suffer from inadequate pain relief. The failure of universally effective therapies is one of the biggest challenges, and as a result, drug treatments fall short, creating unmet medical needs and ongoing demand for more effective treatments.

3. Cost of Treatment: The expensive nature of some PHN treatments, especially advanced neuromodulation equipment and customized therapies, continues to be a barrier for most patients. In other areas, insufficient insurance coverage and budgetary issues deter patients from obtaining the best treatment, which influences market adoption levels.

The post herpetic neuralgia market for treatment is expanding through rising incidence, technological innovation, and transition to pain management through non-opioid options. Despite these, limitations such as slow regulatory processes, limited effectiveness of existing therapies, and high costs of treatment are currently major impediments. Addressing these through innovation, changes in regulations, and enhanced affordability will be essential to further growth in the market and the creation of more effective PHN treatments.

List of Post Herpetic Neuralgia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies post herpetic neuralgia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the post herpetic neuralgia treatment companies profiled in this report include-

• Pfizer
• Arbor Pharma
• Assertio Therapeutics
• Endo Pharma
• Teikoku Pharma
• Teva
• Mylan

Post Herpetic Neuralgia Treatment Market by Segment

The study includes a forecast for the global post herpetic neuralgia treatment market by type, application, and region.

Post Herpetic Neuralgia Treatment Market by Type [Value from 2019 to 2031]:

• Anticonvulsants
• Skin Patch
• Other

Post Herpetic Neuralgia Treatment Market by Application [Value from 2019 to 2031]:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Post Herpetic Neuralgia Treatment Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Post Herpetic Neuralgia Treatment Market

In recent years, the post herpetic neuralgia treatment market has seen considerable growth in different countries like the United States, China, Germany, India, and Japan. The market has been driven by the growth in both pharmaceuticals and other treatments that address the chronic pain of PHN. Major growth drivers of this market include an aging population, greater knowledge about PHN, and innovation in new drugs and technologies. Challenges in the availability of treatment, cost, and regulatory barriers continue, specifically in developing countries. Technological advancements and changing patient requirements are both influencing the growth of the market.

• United States: The United States is still a dominant force in the post herpetic neuralgia Treatment Market, led by developments in pain management therapies. New approvals of drugs, especially new analgesics and nerve-directed treatments, have increased the range of treatments available to patients. The U.S. is also still at the forefront of the use of transcutaneous electrical nerve stimulation (TENS) devices and other non-pharmacological therapies. Furthermore, the growing incidence of herpes zoster infections and heightened awareness of PHN have also stimulated demand for therapies. Healthcare infrastructure and insurance for such treatments also boost market growth in the region.
• China: The post herpetic neuralgia Treatment Market in China is increasing at a rapid pace due to a growing healthcare industry and heightened awareness of PHN. The Chinese government has been enhancing healthcare access, which is predicted to increase the uptake of treatments. Access to sophisticated pain treatment, though, is still challenging in rural China. While drugs rule the marketplace, traditional Chinese medicine (TCM) therapy is being added to treatment plans more and more, with expanding interest in herbal and acupuncture therapies. This blend of conventional and new medicine is anticipated to be instrumental in the development of the market.
• Germany: Germany's post herpetic neuralgia Treatment Market is helped by its highly developed healthcare system and strong pharmaceutical sector. There has been an increase in new drug approvals and availability that help ease PHN pain, including topical and anticonvulsant medications. Germany also places significant emphasis on pain management research, leading to the establishment of non-invasive therapies such as neuromodulation and TENS devices. With the increasing population of the elderly, the need for good PHN treatments is bound to be on the rise. The robust healthcare base also provides improved access to these treatments, fueling market growth.
• India: India is confronted with an upsurge in PHN prevalence, mainly caused by a rise in shingles. The healthcare system of the country has been changing very fast, and treatment for PHN is now more accessible. Affordability is a major issue still, especially in rural India. New trends in the Indian market are the launch of generic forms of newer pain management medications, which have made these treatments affordable. In addition, campaigns regarding PHN and its treatment are picking pace, which may result in more patient interaction and treatment compliance, hence further driving market growth.
• Japan: Japan has a robust healthcare infrastructure, and the treatment scenario for post herpetic neuralgia is progressing steadily. Japan's market has experienced a rise in the use of sophisticated pain management therapies, such as nerve-blocking therapy and the use of technology in pain management. Japan also takes the lead in conducting research into novel drug therapy for PHN, with emphasis on efficacy and safety. The government has been initiating a move to get these drugs more widely available to the elderly, so that effective pain management is accessible to the increasing population of PHN patients.

Features of the Global Post Herpetic Neuralgia Treatment Market

Market Size Estimates: Post herpetic neuralgia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Post herpetic neuralgia treatment market size by type, application, and region in terms of value ($B).

Regional Analysis: Post herpetic neuralgia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the post herpetic neuralgia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the post herpetic neuralgia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the post herpetic neuralgia treatment market by type (anticonvulsants, skin patch, and other), application (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Post Herpetic Neuralgia Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Post Herpetic Neuralgia Treatment Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Post Herpetic Neuralgia Treatment Market by Type
  • 3.3.1: Anticonvulsants
  • 3.3.2: Skin Patch
  • 3.3.3: Other
• 3.4: Global Post Herpetic Neuralgia Treatment Market by Application
  • 3.4.1: Hospital Pharmacies
  • 3.4.2: Online Pharmacies
  • 3.4.3: Retail Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Post Herpetic Neuralgia Treatment Market by Region
• 4.2: North American Post Herpetic Neuralgia Treatment Market
  • 4.2.1: North American Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.2.2: North American Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.3: European Post Herpetic Neuralgia Treatment Market
  • 4.3.1: European Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.3.2: European Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.4: APAC Post Herpetic Neuralgia Treatment Market
  • 4.4.1: APAC Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.4.2: APAC Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.5: ROW Post Herpetic Neuralgia Treatment Market
  • 4.5.1: ROW Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.5.2: ROW Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Application
  • 6.1.3: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Region
• 6.2: Emerging Trends in the Global Post Herpetic Neuralgia Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Post Herpetic Neuralgia Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Post Herpetic Neuralgia Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Arbor Pharma
• 7.3: Assertio Therapeutics
• 7.4: Endo Pharma
• 7.5: Teikoku Pharma
• 7.6: Teva
• 7.7: Mylan